250 results on '"di Grazia, C."'
Search Results
52. Treatment of acute graft-versus-host disease with low-dose, alternate-day antithymocyte globulin
53. Pre-emptive therapy of Epstein-Barr virus (EBV) reactivation after allogeneic hematopoietic stem cell transplant (HSCT) with four courses of i.v. cydofovir: A single centre experience
54. HIGH PROGNOSTIC VALUE OF PRE TRANSPLANT MINIMAL RESIDUAL DISEASE ASSESSMENT BY COMBINED WT1 EXPRESSION AND FLOW CYTOMETRY IN ACUTE MYELOID LEUKEMIA PATIENTS
55. PONATINIB FOR RELAPSE AFTER ALLOGENEIC TRANSPLANTATION IN BCR-ABL plus LEUKEMIAS: PRELIMINARY DATA ON SAFETY AND EFFICACY
56. PREDICTING CHRONIC GRAFT VERSUS HOST DISEASE AND MORTALITY ON DAY+100 AFTER ALLOGENEIC STEM CELL TRANSPLANTATION
57. The contribution of art-therapy and physiotherapy as complementary therapies for bone marrow transplant patients during isolation: the Magnolia Project
58. Allogeneic bone marrow transplantation in patients with hematological malignancy using busulfan, thiotepa, fludarabine as conditioning regimen
59. Thiotepa-based conditioning regimens for allogeneic stem cell transplants: long-term outcome of 374 patients with a median age of 48, grafted from related or unrelated donors
60. Risk factors for non-relapse mortality in 287 patients receiving 1288 donor lymphocyte infusions
61. Reduction of transplant related mortality with time: major improvement for patients allografted with early disease
62. Low mortality rate after diagnosis of invasive aspergillosis in 33 cord blood transplant recipients using direct intrabone injection
63. Long term follow up of the thiotepa 10+ cyclophosphamide 100 conditioning regimen in HLA identical sibling transplants
64. Molecular relapse of acute lymphoblastic leukaemia after allogeneic haematopoietic stem cell transplantation can be successfully treated with donor lymphocyte infusions
65. Total body irradiation and total marrow irradiation for patients with advanced haematologic malignanices undergoing an allogeneic stem cell transplant: a pilot study
66. LIVER IRON CONCENTRATION AND STIFFNESS AND ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION OUTCOMES
67. CYTOGENETIC AND MOLECULAR RISK FACTORS AT DIAGNOSIS ARE OVERCOME BY WT1 AND FLOW CYTOMETRY-BASED PRE TRANSPLANT MINIMAL RESIDUAL DISEASE ASSESSMENT IN ADVANCED ACUTE MYELOID LEUKEMIA PATIENTS
68. Reduced-intensity conditioning (thiotepa plus cyclophosphamide) and rabbit anti-thymocyte globulin for alternative donor transplants
69. Donor lymphocyte infusions (DLI) for mixed chimerism in patients with severe aplastic anemia
70. Prevention of graft versus host disease with Ig M enriched immunoglobulins: a preliminary analysis of a randomized study
71. Successful non-invasive management of late-onset haemorrhagic cystitis in intrabone cord blood transplant recipients
72. Is timing of anti-thymocyte globulin (ATG) - Pre and post-hematopoietic stem cell transplants (HSCT) - Relevant for graft vs. host disease (GvHD)?
73. Toxicity and efficacy of 409 donor lymphocyte infusions for treatment of relapse after allogeneic bone marrow transplantation
74. Unmanipulated haploidentical transplants compared with other alternative donors and matched sibling grafts: a single Center experience in 488 patients
75. A predictive score for transplant related mortality (TRM) following allogeneic stem cell transplantation: day+7 serum cholinesterase, total protein, blood urea nitrogen, gamma glutamyl transferase, donor type and cells dose
76. Reducing transplant-related mortality after allogeneic hematopoietic stem cell transplantation
77. Predicting chronic graft-versus-host disease on day+100 after allogeneic stem cell transplantation
78. Changes in airway responsiveness to methacholine following haematopoietic stem cell transplantation
79. Fast immune recovery following unmanipulated haploidentical BMT with post-transplant high-dose cyclophosphamide as GvHD prophylaxis: a comparison with siblings, unrelated donors, cord blood
80. Conventional hematopoietic stem cell transplants from identical or alternative donors are feasible in recipients relapsing after an autograft
81. MFC-MRD assessment may drive post induction consolidation in intermediate risk AML. Is it time for MRD-DRIVEN approach?
82. Allogeneic hemopoietic stem cell transplantation for patients with myelodisplastic syndrome: The effect of blast count and disease status at transplant
83. Allogeneic hemopoietic stem cell transplantation for patients with lymphoma
84. CHRONIC GRAFT VERSUS HOST DISEASE: HOW MUCH DO WE NEED TO PREVENT RELAPSE?
85. Impact of HLA disparity on GvHD and relapse rate in haploidentical transplants followed by high dose post-transplant cyclophosphamide
86. UNMANIPULATED HAPLOIDENTICAL MARROW TRANSPLANTATION WITH A MODIFIED POST-TRANSPLANT CYCLOPHOSPHAMIDE (PT-CY) REGIMEN: AN UPDATE OF THE GENOVA-ROME GEMELLI EXPERIENCE
87. Improved outcome of alternative donor transplants in patients with myelofibrosis
88. Graft Versus Host Disease and Relapse Free Survival in 470 Patients With Aml or Raeb Grafted from Sibling, Unrelated or Haploidentical Donors
89. Hemorrhages following allogeneic HSCT: incidence and impact on transplant outcome
90. Secondary prophylaxis with voriconazole in patients undergoing stem cell transplantation with previous invasive aspergillosis
91. THE CHOICE OF CUT OFF VALUE AT DIFFERENTTIME POINTS IS CRUCIAL TO IMPROVE THE PROGNOSTIC ROLE OF MINIMAL RESIDUAL DISEASE EVALUATIONIN ACUTE MYELOID LEUKEMIA
92. Marrow cell dose is a significant predictor of outcome in patients undergoing allogeneic hematopoietic stem cell tranplantation
93. Chronic GVHD is reduced with prophylactic anti-thymocyte globulin in alternative donor transplants
94. Fanconi's anemia cells are relatively resistant to H2O2-induced damage
95. Boost of CD34+-selected peripheral blood cells without further conditioning in patients with poor graft function following allogeneic stem cell transplantation
96. Androgens may boost responses to anti-thymocyte globulin in acquired aplastic anaemia
97. UNMANIPULATED HAPLOIDENTICAL TRANSPLANTS FOR ACUTE MYELOID LEUKEMIA (AML) AND REFRACTORY ANEMIA WITH EXCESS BLASTS (RAEB)
98. Unmanipulated haploidentical bone marrow transplantation for high-risk haematological malignancies using myeloablative conditioning and high-dose post transplantation cyclophosphamide
99. High predictive value of pre transplant minimal residual disease assessment by combinining WT1 expression and flow cytometry in acute myeloid leukemia
100. Non-invasive evaluation of liver iron overload and stiffness in patients undergoing allogeneic stem cell transplantation
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.